This is interesting info Figgs. Looks like Qilu picked up only the rights to the Arbutus HepC drug in some of the Asian countries. Assuming something similar with CYDY, there's still a lot of the world left over for other partnerships and for CYDY to grow organically. Also makes sense to me to let established pharma companies fund and commercialize activities in their countries as they'd be the experts in those locations. It takes a lot of money to re-invent the wheel.